In conclusion, sodium selenate enhances PP2A levels but acts through an alternate pathway to affect membrane potentials and dephosphorylate Tau and GSK3β with implications for therapies in neurodegenerative disease models. The gene discussed is MAPT; the disease is neurodegenerative disease.